Tuesday, Jun 22, 1993

Genentech Issued Pioneering Basic Processes Patent; Files Suit Against Lilly for Infringement

South San Francisco, Calif. -- June 22, 1993 --

Genentech, Inc. today announced that it has been issued U.S. Patent No. 5,221,619 covering basic processes used in recombinant DNA technology to produce useful proteins.

"Already the subject of 28 license agreements, this patent is the result of the pioneering research of Drs. Keiichi Itakura and Arthur D. Riggs at the City of Hope National Medical Center," said Dr. Stephen Raines, Genentech's vice president of Intellectual Property. "Their research led to the production of the first useful protein by recombinant DNA technology, which is widely acknowledged as one of the most significant scientific achievements of this century."

Immediately upon issuance of this patent, Genentech filed suit for patent infringement against Eli Lilly and Company in the U.S. District Court for the Northern District of California. This suit concerns Lilly's manufacture of growth hormone, which is also the subject of other litigation between Genentech and Lilly.

Genentech manufactures human growth hormone and markets it under the tradename Protropin® for the treatment of growth hormone deficiency.

Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant medical needs. The company has headquarters in South San Francisco, California and is traded on the New York and Pacific Stock exchanges under the symbol GNE.

# # #